Clinical trial
A Phase 1, Open-Label Study to Assess the Enzyme Inducing Effects of Carbamazepine on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
NCT07279233 is registered in ClinicalTrials.gov with SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label Study to Assess the Enzyme Inducing Effects of Carbamazepine on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 15, 2025
- Completion date
- February 27, 2026
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy, volunteer